Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation

Transplantation

Volumn 93, Issue 8, 2012, Pages 806-812

  Hooper, David K ^a,b   Fukuda, Tsuyoshi ^a,b   Gardiner, Rhonda ^a   Logan, Barbara ^a   Roy Chaudhury, Ashwini ^a   Kirby, Cassie L ^a   Vinks, Alexander A ^a,b   Goebel, Jens ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cytochrome P450; Drug interaction; Hypertension; Kidney transplantation; Pharmacogenetics; Tacrolimus; Tacrolimus toxicity

Indexed keywords

AMLODIPINE; METRONIDAZOLE; NICARDIPINE; NIFEDIPINE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYP3A5 GENE; DOSE ADJUSTED MAXIMUM 12 HOUR TROUGH LEVEL; DRUG ANTAGONISM; FEMALE; GENE; GENOTYPE; HOMOZYGOTE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MAXIMUM 12 HOUR TROUGH LEVEL; OLIGURIA; PHARMACOGENETICS; PHARMACOLOGICAL PARAMETERS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TIME TO MAXIMUM 12 HOUR TROUGH LEVEL; TREMOR;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; NICARDIPINE; RISK; TACROLIMUS; YOUNG ADULT;

EID: 84859630775     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318247a6c7     Document Type: Article

References (22)

1. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41: 813.
2. Iwasaki K. Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 2007; 22: 328.
3. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
4. Kuypers DR, de Jonge H, Naesens M, et al. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82: 711.
5. Kuypers DR, de Jonge H, Naesens M, et al. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet Genomics 2008; 18: 861.
6. Renbarger JL, McCammack KC, Rouse CE, et al. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008; 50: 769.
7. Prasad TN, Stiff DD, Subbotina N, et al. FK 506 (Tacrolimus) metabolism by rat liver microsomes and its inhibition by other drugs. Res Commun Chem Pathol Pharmacol 1994; 84: 35.
8. Hooper DK, Carle AC, Schuchter J, et al. Interaction between tacrolimus and intravenous nicardipine in the treatment of post-kidney transplant hypertension at pediatric hospitals. Pediatr Transplant 2011; 15: 88.
9. Bourbigot B, Guiserix J, Airiau J, et al. Nicardipine increases cyclosporin blood levels. Lancet 1986; 1: 1447. (Pubitemid 16122535)
10. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin. Lancet 1986; 2: 523. (Pubitemid 16049550)
11. Seifeldin RA, Marcos-Alvarez A, Gordon FD, et al. Nifedipine interaction with tacrolimus in liver transplant recipients. Ann Pharmacother 1997; 31: 571.
12. MacPhee IA, Fredericks S, Tai T, et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914.
13. McConn DJ 2nd, Lin YS, Allen K, et al. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complexforming drugs. Drug Metab Dispos 2004; 32: 1083.
14. Bunchman TE, Brookshire CA. Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. J Clin Invest 1991; 88: 310.
15. Neumayer HH, Wagner K. Prevention of delayed graft function in cadaver kidney transplants by diltiazem: Outcome of two prospective, randomized clinical trials. J Cardiovasc Pharmacol 1987; 10(suppl 10): S170.
16. Chan C, Maurer J, Cardella C, et al. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients. Transplantation 1997; 63: 1435.
17. Kuypers DR, Neumayer HH, Fritsche L, et al. Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study. Transplantation 2004; 78: 1204.
18. Duggan KA, Macdonald GJ, Charlesworth JA, et al. Verapamil prevents post-transplant oliguric renal failure. Clin Nephrol 1985; 24: 289.
19. Graham DJ, Dow RJ, Hall DJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 1985; 20(suppl 1): 23S.
20. Zhang GM, Li L, Chen WQ, et al. [Population pharmacokinetics of tacrolimus in Chinese renal transplant patients]. Yao Xue Xue Bao 2008; 43: 695.
21. Wallemacq P, Armstrong VW, Brunet M, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: Report of the European consensus conference. Ther Drug Monit 2009; 31: 139.
22. Fukuen S, Fukuda T, Maune H, et al. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics 2002; 12: 331.